First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz‐Ares; Tudor‐Eliade Ciuleanu; Manuel Cobo; Michael Schenker; Bogdan Żurawski; J. Menezes; Eduardo Richardet; Jaafar Bennouna; Enriqueta Felip; Óscar Juan; Aurelia Alexandru; Hiroshi Sakai; Alejo Lingua; Pamela Salman; Pierre-Jean Souquet; Pedro De Marchi; Claudio Martín; M. Pérol; Arnaud Scherpereel; Shun Lü; Thomas John; David P. Carbone; S. Meadows–Shropshire; Shruti Agrawal; Abderrahim Oukessou; Jinchun Yan; Martin Reck

doi:10.1016/s1470-2045(20)30641-0

Keywords

IpilimumabNivolumabMedicineClinical endpointInternal medicineLung cancerChemotherapyInterim analysisPhases of clinical researchOncologyResponse Evaluation Criteria in Solid TumorsClinical trialCancerSurgeryImmunotherapy

Affiliated Institutions

Related Publications

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West , Michael McCleod , Maen Hussein +17 more

Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer ...

2019 The Lancet Oncology 1597 citations

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Matthew D. Hellmann , Luis Paz‐Ares , Reyes Bernabé +23 more

First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expr...

2019 New England Journal of Medicine 2696 citations

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok , Vanna Chiarion‐Sileni , René González +30 more

Among patients with advanced melanoma, significantly longer overall survival occurred with combination therapy with nivolumab plus ipilimumab or with nivolumab alone than with i...

2017 New England Journal of Medicine 5260 citations

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Matthew D. Hellmann , Tudor‐Eliade Ciuleanu , Adam Płużański +21 more

Progression-free survival was significantly longer with first-line nivolumab plus ipilimumab than with chemotherapy among patients with NSCLC and a high tumor mutational burden,...

2018 New England Journal of Medicine 3061 citations

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

James Larkin , Vanna Chiarion‐Sileni , René González +28 more

Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipilimu...

2015 New England Journal of Medicine 7913 citations

Publication Info

Year: 2021
Type: article
Volume: 22
Issue: 2
Pages: 198-211
Citations: 1273
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1273

OpenAlex

Cite This

APA Style

                            
                                
                                    Luis Paz‐Ares, 
                                
                                    Tudor‐Eliade Ciuleanu, 
                                
                                    Manuel Cobo
                                
                                et al.
                            
                            (2021). 
                            First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. 
                            The Lancet Oncology
                            , 22
                            (2)
                            , 198-211.
                            https://doi.org/10.1016/s1470-2045(20)30641-0
                        

Identifiers

DOI: 10.1016/s1470-2045(20)30641-0